Professor Li Jin: China's cancer innovation drug research and development, their own things to do their own!

(Health Times Media Group Wen Wei Yu Jiali Yang Qiuyu)
" In developed countries in Europe and the United States, research focuses on their own areas of high-risk cancer, such as breast cancer, lung cancer, prostate cancer, so in these areas out of a lot of new drugs, but China's high incidence of cancer such as liver cancer, stomach cancer, esophageal cancer, thyroid cancer is relatively low attention. Therefore, we treat Chinese cancer patients, simply can not wait for other countries to develop new drugs, their own problems to solve, their own things to do! "At the 22th National Conference on Clinical Oncology and the 2019 Annual Meeting of the Chinese Society of Clinical Oncology (CSCO), Professor Li Jin said.Professor Li Jin
Li Jin, director of the Chinese Society of Clinical Oncology (CSCO) , said that in this piece, Chinese researchers are not without their own precedents, such as Harbin HemaCancer Institute Director, China Clinical Oncology Society (CSCO) Vice President Professor Ma Jun has made toxic frost into a good treatment for leukemia. Happily, with the increasing influence of CSCO in the international oncology community, more and more Chinese scholars are participating in asco and the European Society of Oncology (ESMO) exchanges, more and more research results are being presented on the platform of the CSCO annual conference.
but at this stage, the problem is still more, such as the current level of research and development and the gap between the United States is still relatively large, for example, now we approved several drugs are foreign research and development into the country, but the United States approved 17 new drugs a year are developed by Europe and the United States.
Chinese enterprises have taken a lot of detours, such as always follow others, such as do not seem to do PD-1, it is not an innovative research and development enterprises, thousands of troops crowded into a drug on the wooden bridge, fratricidal, miserable. To this end, this annual conference set up the 2019 Innovative Drug Clinical Research Symposium, many of the top academic leaders in the clinical oncology community have contributed to the presentation.
in addition, it is well known that China's population is only 1/5 of the global population, but the incidence and mortality of liver cancer are more than half of the global ratio, in addition, in the etiology of liver cancer, epidemiological characteristics, molecular biology behavior, clinical performance, diagnosis and staging, as well as treatment strategies, are many different, that is, high tumor heterogeneity. Therefore, the General Assembly set up an international hepatobiliary pancreas special session, focusing on primary liver cancer diagnosis and treatment research.
this year's State Food and Drug Administration Drug Review Center (CDE)/CSCO joint session will share cases with CDE review experts, and clinical experts to jointly discuss the exchange of academic views and research and development strategies, for China's anti-tumor innovative drugs research and development to provide new ideas.Professor Li Jin,
, expects industry and regulatory companies to shoulder their social responsibilities, solve the problem of homogenization competition, and provide more good medicines for the treatment of local diseases, so as to contribute their own strength to the country.
.